New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
07:32 EDTPOZNPOZEN submits PA8140/PA32540 Phase 1 final study report
POZEN announced that they have submitted the final study report for the Phase 1 study comparing the pharmacokinetic profile of the omeprazole component of PA8140 tablets to that of PA32540 tablets as agreed with the U.S. Food and Drug Administration.
News For POZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
07:42 EDTPOZNPOZEN receives three patents from USPTO
POZEN (POZN) announced that it has received three patents from the United States Patent and Trademark Office, entitled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs” that cover the U.S. approved product VIMOVO. All three patents are expected to expire in 2022. Horizon Pharma (HZNP), which holds the U.S. NDA for VIMOVO, and POZEN plan to list U.S. patents 8,858,996 and 8,852,636 in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use